PIOGLITAZONE HCL AND METFORMIN HCL vs PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

Compare PIOGLITAZONE HCL AND METFORMIN HCL (Pioglitazone HCL and Metformin HCL) and PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE (Pioglitazone Hydrochloride and Metformin Hydrochloride) — clinical data, side effects, and patient experiences.

PIOGLITAZONE HCL AND METFORMIN HCL

Pioglitazone HCL and Metformin HCL · Biguanide

How it works

12.1 Mechanism of Action Pioglitazone and metformin hydrochloride tablets combine two antihyperglycemic agents: pioglitazone and metformin. Pioglitazone Pioglitazone is a thiazolid...

Approved for

1 INDICATIONS AND USAGE Pioglitazone and metformin hydrochloride tablets

are a combination of pioglitazone

a thiazolidinedione agonist of peroxisome proliferator receptor gamma

and metformin hydrochloride (HCl)

OralTablet

PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

Pioglitazone Hydrochloride and Metformin Hydrochloride · Biguanide

How it works

12.1 Mechanism of Action Pioglitazone and metformin hydrochloride combines two antihyperglycemic agents: pioglitazone and metformin. Pioglitazone Pioglitazone is a thiazolidinedion...

Approved for

a thiazolidinedione agonist of peroxisome proliferator receptor gamma

and metformin hydrochloride

a biguanide

OralTablet

Quick Comparison

PIOGLITAZONE HCL AND METFORMIN HCLPIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

Drug Class

Biguanide

Route

Oral

Half-Life

—

FDA Approved

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

PIOGLITAZONE HCL AND METFORMIN HCL

Nausea

1-10%

Weight Loss

1-10%

Diarrhea

1-10%

Drug Not Working

0.1-1%

Fatigue

0.1-1%

Shortness of Breath

0.1-1%

Vomiting

0.1-1%

Dizziness

0.1-1%

PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

Nausea

1-10%

Weight Loss

1-10%

Diarrhea

1-10%

Drug Not Working

0.1-1%

Fatigue

0.1-1%

Shortness of Breath

0.1-1%

Vomiting

0.1-1%

Dizziness

0.1-1%

FDA Warnings

PIOGLITAZONE HCL AND METFORMIN HCL

5 WARNINGS AND PRECAUTIONS • Congestive heart failure: Fluid retention may occur and can exacerbate or lead to congestive heart failure
Combination use with insulin and use in congestive heart failure NYHA Class I and II may increase risk
3 ) • Hypoglycemia: Consider a lower dose of insulin or insulin secretagogue to reduce risk of hypoglycemia when used in combination with pioglitazone and metformin hydrochloride tablets
4 ) • Hepatic effects: Postmarketing reports of hepatic failure, sometimes fatal

PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

5 WARNINGS AND PRECAUTIONS Congestive heart failure: Fluid retention may occur and can exacerbate or lead to congestive heart failure
Combination use with insulin and use in congestive heart failure NYHA Class I and II may increase risk
3 ) Hypoglycemia: Consider a lower dose of insulin or insulin secretagogue to reduce risk of hypoglycemia when used in combination with pioglitazone and metformin hydrochloride
4 ) Hepatic effects: Postmarketing reports of hepatic failure, sometimes fatal

Clinical Trial Data

No head-to-head clinical studies found for PIOGLITAZONE HCL AND METFORMIN HCL vs PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE.

PIOGLITAZONE HCL AND METFORMIN HCL vs PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE: What You Should Know

Key Differences

Both PIOGLITAZONE HCL AND METFORMIN HCL and PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE belong to the Biguanide class. While they share a similar mechanism of action, differences in pharmacokinetics, dosing, and side effect profiles may make one more suitable than the other for individual patients.

Shared Indications

Both medications are approved for a thiazolidinedione agonist of peroxisome proliferator receptor gamma, a biguanide. When two drugs treat the same condition, the choice between them often depends on the patient's medical history, other medications, tolerability, and prescriber preference.

Safety Considerations

PIOGLITAZONE HCL AND METFORMIN HCL carries 4 FDA warnings. PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE carries 4 FDA warnings. Patients should discuss all warnings and contraindications with their healthcare provider before starting or switching medications..

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.

Related Comparisons

Metformin vs PIOGLITAZONE HCL AND METFORMIN HCL→Metformin vs PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE→METFORMIN ER 500 MG vs PIOGLITAZONE HCL AND METFORMIN HCL→METFORMIN ER 500 MG vs PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE→METFORMIN HCL vs PIOGLITAZONE HCL AND METFORMIN HCL→METFORMIN HCL vs PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE→

Loading comparison data...

PIOGLITAZONE HCL AND METFORMIN HCL vs PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

PIOGLITAZONE HCL AND METFORMIN HCL

Pioglitazone HCL and Metformin HCL · Biguanide

How it works

12.1 Mechanism of Action Pioglitazone and metformin hydrochloride tablets combine two antihyperglycemic agents: pioglitazone and metformin. Pioglitazone Pioglitazone is a thiazolid...

Approved for

1 INDICATIONS AND USAGE Pioglitazone and metformin hydrochloride tablets

are a combination of pioglitazone

a thiazolidinedione agonist of peroxisome proliferator receptor gamma

and metformin hydrochloride (HCl)

OralTablet

PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

Pioglitazone Hydrochloride and Metformin Hydrochloride · Biguanide

How it works

12.1 Mechanism of Action Pioglitazone and metformin hydrochloride combines two antihyperglycemic agents: pioglitazone and metformin. Pioglitazone Pioglitazone is a thiazolidinedion...

Approved for

a thiazolidinedione agonist of peroxisome proliferator receptor gamma

and metformin hydrochloride

a biguanide

OralTablet

Quick Comparison

PIOGLITAZONE HCL AND METFORMIN HCLPIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

Drug Class

Biguanide

Route

Oral

Half-Life

—

FDA Approved

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

PIOGLITAZONE HCL AND METFORMIN HCL

Nausea

1-10%

Weight Loss

1-10%

Diarrhea

1-10%

Drug Not Working

0.1-1%

Fatigue

0.1-1%

Shortness of Breath

0.1-1%

Vomiting

0.1-1%

Dizziness

0.1-1%

PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

Nausea

1-10%

Weight Loss

1-10%

Diarrhea

1-10%

Drug Not Working

0.1-1%

Fatigue

0.1-1%

Shortness of Breath

0.1-1%

Vomiting

0.1-1%

Dizziness

0.1-1%

FDA Warnings

PIOGLITAZONE HCL AND METFORMIN HCL

5 WARNINGS AND PRECAUTIONS • Congestive heart failure: Fluid retention may occur and can exacerbate or lead to congestive heart failure
Combination use with insulin and use in congestive heart failure NYHA Class I and II may increase risk
3 ) • Hypoglycemia: Consider a lower dose of insulin or insulin secretagogue to reduce risk of hypoglycemia when used in combination with pioglitazone and metformin hydrochloride tablets
4 ) • Hepatic effects: Postmarketing reports of hepatic failure, sometimes fatal

PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

5 WARNINGS AND PRECAUTIONS Congestive heart failure: Fluid retention may occur and can exacerbate or lead to congestive heart failure
Combination use with insulin and use in congestive heart failure NYHA Class I and II may increase risk
3 ) Hypoglycemia: Consider a lower dose of insulin or insulin secretagogue to reduce risk of hypoglycemia when used in combination with pioglitazone and metformin hydrochloride
4 ) Hepatic effects: Postmarketing reports of hepatic failure, sometimes fatal

Clinical Trial Data

No head-to-head clinical studies found for PIOGLITAZONE HCL AND METFORMIN HCL vs PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE.

PIOGLITAZONE HCL AND METFORMIN HCL vs PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE: What You Should Know

Key Differences

Shared Indications

Safety Considerations

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.